Anumana’s AI algorithm for cardiac amyloidosis gets FDA breakthrough nod
Related Articles
Midwest providers eye new financial opportunities
Modern Healthcare: Mayo Clinic announced a new technology platform initiative to deliver the next generation of clinical decision support tools, diagnostic insights and care recommendations to help clinicians make faster…{post_date: F d, Y}
Anumana Named to Fierce Medtech’s 2022 Fierce 15
AI-driven startup from nference and Mayo Clinic Platform positioned to transform cardiac care{post_date: F d, Y}
Tackling Imbalanced Regression in Clinical AI with KDE-weighted Deep Models
Clinical AI systems often include automated analysis of medical time series, such as electrocardiogram (ECG), to serve as valuable diagnostic decision support tools. While many cardiovascular diseases are traditionally measured…{post_date: F d, Y}
Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease
Companies initiate research agreement supporting development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosis{post_date: F d, Y}